Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Small conductance calcium-activated potassium channel protein 3 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | 6-phosphofructokinase | 0.0107 | 0.2503 | 0.2715 |
Loa Loa (eye worm) | hypothetical protein | 0.0064 | 0.0937 | 0.0937 |
Trichomonas vaginalis | chromobox protein, putative | 0.0041 | 0.0107 | 0.0426 |
Echinococcus granulosus | 6 phosphofructokinase | 0.0107 | 0.2503 | 0.2715 |
Treponema pallidum | diphosphate--fructose-6-phosphate 1-phosphotransferase | 0.0107 | 0.2503 | 0.5 |
Trichomonas vaginalis | chromobox protein, putative | 0.0041 | 0.0107 | 0.0426 |
Trichomonas vaginalis | phosphofructokinase, putative | 0.0107 | 0.2503 | 1 |
Loa Loa (eye worm) | phosphofructokinase | 0.0107 | 0.2503 | 0.2503 |
Trypanosoma brucei | ATP-dependent 6-phosphofructokinase, glycosomal | 0.0107 | 0.2503 | 0.5 |
Trichomonas vaginalis | phosphofructokinase, putative | 0.0107 | 0.2503 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0071 | 0.1205 | 0.1205 |
Brugia malayi | 6-phosphofructokinase | 0.0107 | 0.2503 | 0.8424 |
Entamoeba histolytica | phosphofructokinase, putative | 0.0107 | 0.2503 | 0.5 |
Entamoeba histolytica | phosphofructokinase, putative | 0.0107 | 0.2503 | 0.5 |
Mycobacterium ulcerans | 6-phosphofructokinase | 0.0107 | 0.2503 | 0.5 |
Entamoeba histolytica | phosphofructokinase, putative | 0.0107 | 0.2503 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0107 | 0.2503 | 0.2715 |
Brugia malayi | phosphofructokinase | 0.0107 | 0.2503 | 0.8424 |
Echinococcus granulosus | small conductance calcium activated potassium | 0.021 | 0.6267 | 1 |
Loa Loa (eye worm) | heterochromatin protein 1 | 0.0069 | 0.1101 | 0.1101 |
Trichomonas vaginalis | phosphofructokinase, putative | 0.0107 | 0.2503 | 1 |
Loa Loa (eye worm) | 6-phosphofructokinase | 0.0107 | 0.2503 | 0.2503 |
Mycobacterium tuberculosis | Probable 6-phosphofructokinase PfkA (phosphohexokinase) (phosphofructokinase) | 0.0107 | 0.2503 | 0.5 |
Brugia malayi | hypothetical protein | 0.012 | 0.2972 | 1 |
Leishmania major | ATP-dependent phosphofructokinase | 0.0107 | 0.2503 | 0.5 |
Trichomonas vaginalis | chromobox protein, putative | 0.0069 | 0.1101 | 0.4396 |
Brugia malayi | Heterochromatin protein 1 | 0.0069 | 0.1101 | 0.3703 |
Onchocerca volvulus | Heterochromatin protein 1 homolog | 0.0041 | 0.0107 | 1 |
Trypanosoma cruzi | ATP-dependent 6-phosphofructokinase, glycosomal | 0.0107 | 0.2503 | 0.5 |
Loa Loa (eye worm) | 6-phosphofructokinase | 0.0107 | 0.2503 | 0.2503 |
Schistosoma mansoni | hypothetical protein | 0.021 | 0.6267 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.021 | 0.6267 | 0.6267 |
Loa Loa (eye worm) | hypothetical protein | 0.0068 | 0.1064 | 0.1064 |
Brugia malayi | 6-phosphofructokinase | 0.0107 | 0.2503 | 0.8424 |
Echinococcus multilocularis | small conductance calcium activated potassium | 0.021 | 0.6267 | 1 |
Schistosoma mansoni | calcium-activated potassium channel | 0.0136 | 0.3546 | 0.4733 |
Trichomonas vaginalis | phosphofructokinase, putative | 0.0107 | 0.2503 | 1 |
Trichomonas vaginalis | chromobox protein, putative | 0.0069 | 0.1101 | 0.4396 |
Echinococcus multilocularis | 6 phosphofructokinase | 0.0107 | 0.2503 | 0.2715 |
Schistosoma mansoni | calcium-activated potassium channel | 0.021 | 0.6267 | 1 |
Mycobacterium leprae | PROBABLE 6-PHOSPHOFRUCTOKINASE PFKA (PHOSPHOHEXOKINASE) (PHOSPHOFRUCTOKINASE) | 0.0107 | 0.2503 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EMR (binding) | = 1.1 | Inhibition of KCa2.3 in Sprague-Dawley rat superior cervical ganglion neurons assessed as inhibition of afterhyperpolarization by electrophysiological assay relative to UCL1848 | ChEMBL. | 23685886 |
IC50 (binding) | = 3 nM | Inhibition of KCa2.3 in Sprague-Dawley rat superior cervical ganglion neurons assessed as inhibition of afterhyperpolarization by electrophysiological assay | ChEMBL. | 23685886 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.